Payers growing influence on R&D decision making

@article{Hughes2008PayersGI,
  title={Payers growing influence on R\&D decision making},
  author={Bethan Hughes},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={876-878}
}
A recent report from the European Commission highlights the increasing importance of payer considerations in demonstrating product value through clinical development programmes. 
Reflections on the evolution of health technology assessment in Europe
TLDR
How HTA has evolved over time as well as its impact on policy and practice in Europe over the last decade is explored, with a focus on England, France, Germany and Sweden. Expand
Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
TLDR
Investing in CER can help address the current gap in publicly available, credible, up-to-date, and scientifically based comparative information on the effectiveness of drugs and other health interventions, thereby facilitating access to and public and private investment in the most beneficial new drugs and technologies. Expand
Comparative effectiveness research and evidence-based health policy: experience from four countries.
CONTEXT The discussion about improving the efficiency, quality, and long-term sustainability of the U.S. health care system is increasingly focusing on the need to provide better evidence forExpand
Toward effective health technology regulation
New health technologies offer both challenges and opportunities. Regulation is one mechanism to help balance the benefits and risks of new health technologies. This thesis examines the extent toExpand
The structure and business of biopharmaceutical companies including the management of risks and resources
Successful drugs have a good return on investment by bringing in considerably more revenue than the expenses of discovery, development, and manufacturing. Successful drugs pay for all drug projects,Expand
Benefit–risk assessment: the use of clinical utility index
  • D. Ouellet
  • Medicine
  • Expert opinion on drug safety
  • 2010
TLDR
The use of a clinical utility index (CUI) for quantitative assessment of benefit/risk is most useful when there are multiple attributes involved in a decision to better understand the relevance of each attribute and when differentiation from competitors is critical to the success of a compound. Expand
A Theoretical Evidence: The Mediating Role Of Creativity On The Relationship Between Knowledge Management And Entrepreneurial Orientation Toward Innovation Performance In The Jordanian Smes
This research paper explored the importance of innovation performance in the Jordanian SMEs industry, according to the signif icant impact of the industry on the economy worldwide. Mainly, the mostExpand
Teacher counselors’ and pupils’ perceptions of correctional strategies used by teachers and their impact on pupils' socio-emotional development in primary schools in Kericho County, Kenya
The issue of pupils‘ correction in primary schools is perceived as an intricate affair that requires well designed and thought out approaches in order to ensure pupils‘ proper socio-emotionalExpand
Peregrinaje de un antidiabético hasta su aprobación por las agencias internacionales del medicamento. Situación actual
Resumen El proceso de aprobacion de nuevos antidiabeticos ha experimentado un cambio radical, que implica a la amplitud, la extension y los objetivos de su desarrollo clinico. Se han discutido lasExpand
News feature: 2008 in reflection
...
1
2
...